Marie-Louise Newell

Marie-Louise Newell

Auto-generated profile, based on publicly available information

Marie-Louise Newell

School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2004 in The Lancet
Verified
Journal Article
Closed access
MNMarie-Louise Newell
Marie-Louise Newell
HCHoosen Coovadia
Hoosen Coovadia
MCMarjo Cortina-Borja
Marjo Cortina-Borja
NRNigel Rollins
Nigel Rollins
PGPhilippe Gaillard
Philippe Gaillard
FDFrancois Dabis
Francois Dabis

22 February 2013 in Science
Verified
Journal Article
Closed access
PDF file
FTFrank Tanser
Frank Tanser
TBTill Bärnighausen
Till Bärnighausen
EGErofili Grapsa
Erofili Grapsa
JZJaffer Zaidi
Jaffer Zaidi
MNMarie-Louise Newell
Marie-Louise Newell
Cost-Benefit of ART: In the battle to control HIV, mass antiretroviral treatment (ART) costs $500 to $900 per person per year. Bor et al. (p. 961 ) calculated the impact of intensifying ART on the life expectancy of people living in rural KwaZulu Natal. The dates of death were collected from a population of about 100,000 people during 2000–2011: Four years before and 8 years after the scaling up of ART. Life expectancy of adults increased by more than 11 years after ART was expanded, and the economic value of the lifetimes gained were calculated to far exceed the cost of treatment. Tanser et al. (p. 966 ) followed nearly 17,000 HIV-uninfected individuals in KwaZulu-Natal over an 8-year period. Holding other HIV risk factors constant, individual HIV acquisition risk declined significantly with increasing ART coverage of HIV-infected people.

1 July 2013 in The Lancet Global Health
Verified
Journal Article
Open access
ALAnne Cc Lee
Anne Cc Lee
JKJoanne Katz
Joanne Katz
HBHannah Blencowe
Hannah Blencowe
SCSimon Cousens
Simon Cousens
NKNaoko Kozuki
Naoko Kozuki
RBRobert E Black
Robert E Black
National estimates for the numbers of babies born small for gestational age and the comorbidity with preterm birth are unavailable. We aimed to estimate the prevalence of term and preterm babies born small for gestational age (term-SGA and preterm-SGA), and the relation to low birthweight (<2500 g), in 138 countries of low and middle income in 2010. Small for gestational age was defined as lower than the 10th centile for fetal growth from the 1991 US national reference population. Data from 22 birth cohort studies (14 low-income and middle-income countries) and from the WHO Global Survey on Maternal and Perinatal Health (23 countries) were used to model the prevalence of term-SGA births. Prevalence of preterm-SGA infants was calculated from meta-analyses. In 2010, an estimated 32·4 million infants were born small for gestational age in low-income and middle-income countries (27% of livebirths), of whom 10·6 million infants were born at term and low birthweight. The prevalence of term-SGA babies ranged from 5·3% of livebirths in east Asia to 41·5% in south Asia, and the prevalence of preterm-SGA infants ranged from 1·2% in north Africa to 3·0% in southeast Asia. Of 18 million low-birthweight babies, 59% were term-SGA and 41% were preterm-SGA. Two-thirds of small-for-gestational-age infants were born in Asia (17·4 million in south Asia). Preterm-SGA babies totalled 2·8 million births in low-income and middle-income countries. Most small-for-gestational-age infants were born in India, Pakistan, Nigeria, and Bangladesh. The burden of small-for-gestational-age births is very high in countries of low and middle income and is concentrated in south Asia. Implementation of effective interventions for babies born too small or too soon is an urgent priority to increase survival and reduce disability, stunting, and non-communicable diseases. Bill & Melinda Gates Foundation by a grant to the US Fund for UNICEF to support the activities of the Child Health Epidemiology Reference Group (CHERG).

22 February 2013 in Science
Verified
Journal Article
Closed access
PDF file
JBJacob Bor
Jacob Bor
AHAbraham J. Herbst
Abraham J. Herbst
MNMarie-Louise Newell
Marie-Louise Newell
TBTill Bärnighausen
Till Bärnighausen
Cost-Benefit of ART: In the battle to control HIV, mass antiretroviral treatment (ART) costs $500 to $900 per person per year. Bor et al. (p. 961 ) calculated the impact of intensifying ART on the life expectancy of people living in rural KwaZulu Natal. The dates of death were collected from a population of about 100,000 people during 2000–2011: Four years before and 8 years after the scaling up of ART. Life expectancy of adults increased by more than 11 years after ART was expanded, and the economic value of the lifetimes gained were calculated to far exceed the cost of treatment. Tanser et al. (p. 966 ) followed nearly 17,000 HIV-uninfected individuals in KwaZulu-Natal over an 8-year period. Holding other HIV risk factors constant, individual HIV acquisition risk declined significantly with increasing ART coverage of HIV-infected people.

1 March 2007 in The Lancet
Verified
Journal Article
Closed access
HCHoosen M Coovadia
Hoosen M Coovadia
NRNigel C Rollins
Nigel C Rollins
RBRuth M Bland
Ruth M Bland
KLKirsty Little
Kirsty Little
ACAnna Coutsoudis
Anna Coutsoudis
MNMarie-Louise Newell
Marie-Louise Newell

12 November 2007 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
FTFrank Tanser
Frank Tanser
VHVictoria Hosegood
Victoria Hosegood
TBTill Bärnighausen
Till Bärnighausen
KHKobus Herbst
Kobus Herbst
MNMakandwe Nyirenda
Makandwe Nyirenda
MNMarie-Louise Newell
Marie-Louise Newell
The health and demography of the South African population has been undergoing substantial changes as a result of the rapidly progressing HIV epidemic. Researchers at the University of KwaZulu-Natal and the South African Medical Research Council established The Africa Centre for Health and Population Studies in 1997 funded by a large core grant from The Wellcome Trust, UK. Given the urgent need for high quality longitudinal data with which to monitor these changes, and with which to evaluate interventions to mitigate impact, a demographic surveillance system (DSS) was established in a rural South African population facing a rapid and severe HIV epidemic. 1 The DSS, referred to as the Africa Centre Demographic Information System (ACDIS), started in 2000. In 2003, population-based HIV testing (also funded by the Wellcome Trust, UK) was started in ACDIS through annual surveys. In this article, we seek to describe the most salient features of ACDIS and the population-based HIV cohort and briefly present some of the most important results to date.